Scios Natrecor
Executive Summary
Nesiritide is not approvable for treatment of acute episodes of congestive heart failure, FDA tells company April 27. "The agency determined that further study is needed to define the consequences of the pharmacodynamic profile, specifically as it relates to the onset of effect and the recovery from hypotension if it occurs," the company said. Scios noted that "FDA acknowledged that Natrecor reduced pulmonary capillary wedge pressure, increased cardiac output, and produced some evidence of symptomatic benefit." The product was recommended for approval in treating chronic decompensated CHF by FDA's Cardio-Renal Drugs Advisory Committee in January ("The Pink Sheet" Feb. 1, p. 5)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth